Mexico COFEPRIS Medical Device Registration: The Complete Guide

Why Mexico Matters for Medical Device Companies

Mexico is the second-largest medical device market in Latin America and a strategic priority for any manufacturer looking to expand in the Americas. The Mexican medical device market is projected to reach USD 9.72 billion by 2028, driven by a population of over 130 million, an expanding public healthcare system, a thriving private hospital sector, and the country's deep integration with global supply chains through the USMCA (United States-Mexico-Canada Agreement).

Several factors make Mexico especially attractive for medical device companies:

• Geographic proximity to the United States — Mexico shares a 3,145-kilometer border with the US and is a natural extension of North American commercial strategy. Many manufacturers already operate maquiladora production facilities in Mexico.
• Regulatory modernization — COFEPRIS has been actively reforming its medical device registration processes, including the launch of a new 30-day fast-track equivalency pathway for devices approved by reference authorities such as the FDA, Health Canada, and Japan PMDA.
• USMCA trade advantages — Products manufactured in USMCA member countries benefit from preferential tariff treatment and streamlined regulatory cooperation.
• Growing healthcare spending — Both public (IMSS, ISSSTE) and private healthcare expenditure continue to rise, expanding the addressable market for medical devices.
• Manufacturing hub — Mexico is already a major medical device manufacturing center, particularly in Tijuana, Jalisco, and the Bajio region, producing everything from surgical instruments to advanced diagnostic imaging equipment.

But entering the Mexican market requires navigating COFEPRIS — the Federal Commission for the Protection against Sanitary Risks — and its specific registration requirements. Mexico has its own classification system, its own in-country representative mandate, its own documentation standards, and its own post-market surveillance obligations. This guide covers every aspect of the process so you can plan your market entry with confidence.

COFEPRIS: Mexico's Regulatory Authority

COFEPRIS — Comision Federal para la Proteccion contra Riesgos Sanitarios (Federal Commission for the Protection against Sanitary Risks) — is the federal agency within Mexico's Secretariat of Health (Secretaria de Salud) responsible for regulating medical devices, pharmaceuticals, food safety, environmental health risks, and other products and services that affect public health.

For medical devices, COFEPRIS exercises authority over:

• Pre-market registration and authorization of medical devices and IVDs
• Good Manufacturing Practice (GMP) compliance verification, including recognition of MDSAP certificates
• Import and export control for medical devices entering or leaving Mexico
• Post-market surveillance including adverse event reporting (technovigilance), recalls, and field safety corrective actions
• Advertising and promotion oversight for medical devices
• Market surveillance and inspections of distributors, importers, and healthcare facilities

COFEPRIS operates under Mexico's General Health Law (Ley General de Salud) and its associated regulations, including the Health Supplies Regulation (Reglamento de Insumos para la Salud) and a series of Official Mexican Standards (Normas Oficiales Mexicanas, or NOMs) that specify technical requirements for medical devices.

Key Regulatory Framework

Regulation / Standard	Scope
General Health Law (Ley General de Salud)	Overarching legal framework; Article 376 governs medical device registration validity and renewals
Health Supplies Regulation (Reglamento de Insumos para la Salud)	Detailed procedural requirements for registration, labeling, advertising, and distribution
NOM-241-SSA1-2025	Good Manufacturing Practices for medical devices (updated standard replacing the prior version)
NOM-137-SSA1-2008	Labeling requirements for medical devices; all labeling and IFU must be in Spanish
Mexican Pharmacopoeia	Includes medical device standards and recently updated SaMD guidance
COFEPRIS Equivalency Agreements	Framework for recognizing approvals from FDA, Health Canada, Japan PMDA, and IMDRF/MDSAP

COFEPRIS is a member of the International Medical Device Regulators Forum (IMDRF) and the Pan American Network for Drug Regulatory Harmonization (PANDRH). Its participation in these international bodies has driven the modernization of Mexico's regulatory framework, including the adoption of regulatory reliance principles and the new fast-track pathways.

Device Classification System

Mexico uses a three-class risk-based classification system for medical devices, defined in the General Health Law and the Health Supplies Regulation. The system is broadly aligned with the classification approaches used by other major regulators but uses three classes rather than the four classes used in the EU or Brazil.

Classification Overview

Class	Risk Level	Definition	Examples
Class I	Low risk	Well-known in medical practice; verified safety and efficacy; do not enter the body	Disposable gloves, thermometers, blood pressure monitors, surgical masks, hospital beds
Class II	Medium risk	Well-known in medical practice; may have material variations; may enter the body for less than 30 days	Syringes, wheelchairs, infusion pumps, glucose meters, contact lenses
Class III	High risk	Recently accepted in medical practice; or enter the body for more than 30 days; or life-supporting/life-sustaining	Artificial heart valves, pacemakers, defibrillators, breast implants, cardiovascular stents

Classification Principles

COFEPRIS applies the following principles when determining device classification:

• Duration of body contact — Devices that enter the body for more than 30 days are generally classified higher than those with shorter contact durations.
• Invasiveness — Surgically invasive devices receive higher classification than non-invasive ones.
• Clinical significance — Devices that are life-supporting or life-sustaining are typically Class III regardless of other factors.
• Novelty — Devices that are newly accepted in medical practice may be classified higher than established devices with equivalent functionality.
• Energy source — Active devices (those relying on a power source) may be classified higher depending on their function.

When a device could fall into multiple classes based on different criteria, the highest applicable class governs.

How Mexico's Classification Compares to Other Jurisdictions

Mexico (COFEPRIS)	FDA (US)	EU MDR	Brazil (ANVISA)	Risk Level
Class I	Class I (exempt/510(k))	Class I	Class I / Class II	Low
Class II	Class II (510(k))	Class IIa / Class IIb	Class II / Class III	Medium
Class III	Class III (PMA)	Class III	Class III / Class IV	High

This comparison is approximate. Always verify classification with COFEPRIS directly or through your Mexico Registration Holder, as borderline cases may be classified differently than expected.

Practical tip: If your device is already classified by the FDA or under the EU MDR, that classification provides a useful starting point but is not binding on COFEPRIS. Prepare a classification rationale referencing the General Health Law criteria, and if in doubt, request a classification determination from COFEPRIS before beginning the full registration process.

Mexico Registration Holder (MRH) Requirements

One of the most important structural requirements in the Mexican regulatory framework is that foreign manufacturers must appoint a Mexico Registration Holder (MRH) — a local legal entity authorized to act on the manufacturer's behalf before COFEPRIS. This is not optional; it is a legal prerequisite for registration.

What the MRH Does

The Mexico Registration Holder serves as the legal representative of the foreign manufacturer in Mexico for all regulatory matters. The MRH's responsibilities include:

• Submitting and managing registration applications with COFEPRIS
• Holding the sanitary registration (registro sanitario) on behalf of the foreign manufacturer
• Coordinating import permits and working with Mexican customs authorities
• Serving as the primary point of contact for COFEPRIS communications, inspections, and inquiries
• Managing post-market obligations including technovigilance reporting and registration renewals
• Maintaining distribution records and ensuring traceability of devices placed on the Mexican market

MRH Selection Criteria

Choosing the right MRH is a critical strategic decision. Consider the following:

• Legal entity status — The MRH must be a legally constituted Mexican entity with a valid power of attorney from the manufacturer.
• Regulatory expertise — The MRH should have demonstrated experience with COFEPRIS processes, classification determinations, and registration management.
• Independence vs. distributor model — Some manufacturers appoint an independent regulatory firm as their MRH to maintain control over their registrations, while others appoint their commercial distributor. Each approach has trade-offs.
• Continuity — The MRH holds your registrations. Changing MRH requires a transfer process that can be time-consuming. Choose an entity you expect to work with long-term.
• Technovigilance capability — The MRH must be able to receive and process adverse event reports and communicate with COFEPRIS on your behalf within mandated timeframes.

Practical tip: Many manufacturers make the mistake of appointing their commercial distributor as the MRH without fully considering the implications. If you later decide to change distributors, you may need to transfer your registrations — a process that can take months. Consider using an independent regulatory consulting firm as your MRH to decouple your regulatory and commercial relationships. This gives you flexibility to change distributors without disrupting your market authorization.

Registration Pathways

COFEPRIS offers two primary pathways for medical device registration: the Standard Registration route (full technical review) and the Equivalency route (abbreviated review leveraging existing foreign approvals). The pathway you choose has significant implications for documentation requirements, timelines, and costs.

Standard Route (Full Technical Review)

The Standard Route involves a full technical dossier submission to COFEPRIS. This is the traditional pathway and is required for devices that do not have an existing approval from a recognized reference authority, or when the manufacturer chooses not to use the equivalency pathway.

What the Standard Route requires:

• Full technical dossier including device descriptions, design specifications, and performance data
• Clinical evidence appropriate to the risk class
• Quality system documentation demonstrating GMP compliance
• Complete Spanish-language labeling and instructions for use (IFU)
• Risk analysis documentation
• Biocompatibility data where applicable
• Free Sale Certificate or equivalent

Standard Route timelines:

Submission Type	Expected Timeline
Class I (low risk notification)	20-30 business days
Class II	30-60 business days
Class III	60-180 business days
Standard review (all classes, actual practice)	Approximately 12 months from submission
Third-party review option	3-6 months (additional cost: $2,000-$4,000)

The gap between the statutory review periods and actual practice is well-known. COFEPRIS has historically struggled with backlogs, though the agency has taken steps to address this through third-party review arrangements and process simplification measures introduced in 2025-2026.

Equivalency Route (Abbreviated Pathway)

The Equivalency Route — significantly expanded and operationalized in 2025-2026 — allows manufacturers to leverage existing approvals from recognized reference authorities to obtain Mexican registration through an abbreviated review process. This is the most important recent development in Mexican medical device regulation.

Eligible reference authorities:

• US FDA
• Health Canada
• Japan PMDA
• IMDRF/MDSAP approvals are also recognized under the updated framework

What the Equivalency Route requires:

• Proof of foreign marketing authorization from a recognized reference authority
• Summary technical dossier referencing the existing foreign approval (not a full repeat submission)
• Demonstration of full equivalence between the reference-market device and the device proposed for the Mexican market
• GMP evidence (ISO 13485, MDSAP certificate, or equivalent)
• Compliant Spanish-language labeling and IFU
• Administrative documentation for the MRH

Target review timeline: 30 business days for qualifying submissions under the fast-track pathway (discussed in detail in the next section).

Route Comparison at a Glance

Factor	Standard Route	Equivalency Route
Eligibility	All devices	Devices approved by FDA, Health Canada, or Japan PMDA
Documentation	Full technical dossier	Summary dossier referencing foreign approval
Review timeline	3-12+ months (actual practice)	Target: 30 business days
Cost	Lower government fees; higher preparation cost	Similar government fees; lower preparation cost
Complexity	Higher — full dossier preparation	Lower — leverages existing submissions
Clinical evidence	May require Mexico-specific data	Leverages existing clinical data from reference market
Best for	Devices without reference-market approval	Devices already cleared/approved in US, Canada, or Japan

For the majority of international manufacturers who already hold FDA clearance or approval, the Equivalency Route is the clear preferred pathway for entering Mexico.

The New 30-Day Fast-Track Pathway (2026 Update)

The most significant recent development in Mexican medical device regulation is the operationalization of the fast-track equivalency pathway, which targets a 30-business-day review period for devices already approved by reference authorities. This pathway was formally launched in September 2025 and became fully operational in early 2026.

How the Fast-Track Works

The fast-track pathway is built on the principle of regulatory reliance — COFEPRIS relies on the scientific and technical assessment already performed by a trusted reference authority rather than conducting a full independent review. The key elements are:

1. Eligibility verification — The manufacturer (through the MRH) confirms that the device holds a valid marketing authorization from the FDA, Health Canada, or Japan PMDA.
2. Equivalence demonstration — The submission must demonstrate that the device proposed for the Mexican market is fully equivalent to the device approved by the reference authority. Any differences in intended use, design, materials, or manufacturing must be identified and justified.
3. Summary dossier — Rather than submitting a full technical dossier, the manufacturer submits a summary referencing the existing foreign approval, including key technical data, labeling, and GMP evidence.
4. Spanish-language compliance — All labeling and IFU must comply with NOM-137-SSA1-2008 and be provided in Spanish.
5. Administrative completeness — The MRH documentation, letters of authorization, and all administrative forms must be complete and correct.

Requirements for Fast-Track Eligibility

• Valid marketing authorization from FDA (510(k) clearance, De Novo, or PMA approval), Health Canada (Medical Device License), or Japan PMDA
• The reference-market device and the Mexican-market device must be fully equivalent
• GMP compliance demonstrated through ISO 13485 certification, MDSAP certificate, CE marking, or equivalent
• Complete and compliant Spanish-language labeling
• No outstanding regulatory actions, suspensions, or restrictions in the reference market

What Can Go Wrong

The 30-day target is ambitious, and not all submissions meet it. Common reasons for delays include:

• Incomplete equivalence demonstration — If COFEPRIS identifies differences between the reference-market device and the Mexican submission that are not adequately explained, additional information will be requested, pausing the clock.
• Administrative deficiencies — Missing documents, incorrect forms, or inadequate MRH authorization letters are the most common cause of rejection or delay.
• Labeling non-compliance — Spanish translations that do not meet NOM-137 requirements or that contain discrepancies with the original labeling.
• Classification mismatch — If COFEPRIS disagrees with the proposed classification, the review may be delayed while classification is resolved.

Practical tip: The fast-track pathway dramatically reduces time-to-market for Mexico, but it only works if the submission is complete and correct the first time. Invest in thorough preparation, especially the equivalence documentation and Spanish labeling compliance. A well-prepared fast-track submission can genuinely achieve authorization in 30-45 business days; a poorly prepared one can take longer than the standard route due to back-and-forth information requests.

Documentation Requirements

The documentation required for COFEPRIS registration depends on the registration route and the device classification. Below is a comprehensive breakdown.

Core Documentation (All Routes and Classes)

The following documents are required regardless of the pathway or risk class:

Document	Notes
Free Sale Certificate (FSC) or Foreign Government Certificate	Issued by the country of origin; must be legalized/apostilled
Certificate of Good Manufacturing Practices / ISO 13485 / MDSAP Certificate	Demonstrates quality system compliance
Device Identification Form	Device name, model, classification, intended use
Technical Specifications	Dimensions, materials, performance characteristics
Risk Analysis	Per ISO 14971 or equivalent
Labeling Samples in Spanish	Per NOM-137-SSA1-2008
Instructions for Use (IFU) in Spanish	Required for all devices that require user instructions
Letter of Representation / Authorization for MRH	Legal authorization for the Mexico Registration Holder
Power of Attorney	Legalizing the MRH relationship
Certificate of Incorporation (manufacturer)	Company registration from country of origin

Additional Documentation by Class

Class	Additional Requirements
Class I	Generally no additional requirements beyond core documentation
Class II	Performance testing data; may require biocompatibility data depending on body contact
Class III	Clinical evidence; biocompatibility data; more detailed risk analysis; may require Mexico-specific clinical data in some cases

Additional Documentation for Equivalency Route

When using the fast-track equivalency pathway, the following additional documents are required:

Document	Notes
Proof of Foreign Marketing Authorization	Copy of FDA 510(k)/PMA letter, Health Canada MDL, or Japan PMDA approval
Equivalence Justification	Detailed comparison demonstrating the device for Mexico is equivalent to the reference-market device
Reference Market Labeling	Original labeling from the reference market (for comparison)
GMP Evidence	MDSAP audit report, ISO 13485 certificate, or CE mark documentation

Spanish Language Requirements

All labeling and IFU must be in Spanish and must comply with NOM-137-SSA1-2008. This includes:

• Device name and description
• Intended use and indications
• Contraindications, warnings, and precautions
• Instructions for use
• Manufacturer name and address
• MRH name and address in Mexico
• Storage and handling conditions
• Expiration date or shelf life
• Sterilization method (if applicable)
• Lot or serial number identification
• Country of manufacture

Translations must be accurate and technically precise. COFEPRIS may request corrections if the Spanish labeling does not adequately reflect the source documentation.

The Registration Process: Step by Step

The following steps outline the complete registration process for medical devices in Mexico.

Step 1: Classification Determination

Before beginning any registration work, determine the correct COFEPRIS classification for your device. This can be done by:

• Self-classifying based on the General Health Law criteria
• Requesting a formal classification determination from COFEPRIS
• Working with your MRH to obtain a classification opinion

If you are unsure about classification, invest the time to get it right before proceeding. An incorrect classification will delay the entire process.

Step 2: Appoint a Mexico Registration Holder

Select and contract with a qualified MRH. Execute the necessary legal documentation including:

• Letter of Authorization
• Power of Attorney
• Confidentiality agreements
• Service agreement defining roles and responsibilities

The MRH must be appointed before any submissions can be made to COFEPRIS.

Step 3: Prepare Documentation

Compile the required documentation based on your registration route:

• Standard Route: Prepare a full technical dossier including clinical evidence, performance testing, risk analysis, and complete quality system documentation.
• Equivalency Route: Prepare the summary dossier, equivalence justification, and all supporting documentation from the reference authority approval.

All documents must be translated into Spanish where required, and foreign documents must be legalized or apostilled as appropriate.

Step 4: Compile the COFEPRIS Submission

The MRH compiles the complete submission package in the format required by COFEPRIS, including:

• Completed application forms
• Administrative documentation for the MRH
• Technical documentation organized per COFEPRIS requirements
• Payment of government fees

Step 5: Submit to COFEPRIS

The MRH submits the application to COFEPRIS on behalf of the manufacturer. For the fast-track equivalency pathway, the submission is directed to the specific abbreviated review process.

Step 6: COFEPRIS Review

COFEPRIS reviews the submission. The review timeline depends on the pathway:

• Fast-track equivalency: Target 30 business days
• Standard route (Class I): 20-30 business days (statutory)
• Standard route (Class II): 30-60 business days (statutory)
• Standard route (Class III): 60-180 business days (statutory)
• Actual timelines (standard route): 12+ months in practice

During review, COFEPRIS may issue requests for additional information. Responding promptly and completely through the MRH is critical to avoiding delays.

Step 7: Registration Granted

Upon successful review, COFEPRIS issues the sanitary registration (registro sanitario). The registration is valid for 5 years initially and must be renewed before expiration.

Step 8: Import Authorization and Market Launch

With the sanitary registration in hand, the MRH or authorized importer can obtain the necessary import permits (particularly important for Class III devices) and begin commercial distribution in Mexico.

Fees and Costs

Understanding the full cost picture for COFEPRIS registration requires looking at both government fees and the broader costs of compliance.

COFEPRIS Government Fees (2026)

The following are the official COFEPRIS government fees for medical device registration in 2026:

Item	Fee (MXN)	Approximate USD
Class I / Low Risk — New Registration	$16,499	~$933
Class II — New Registration	$24,198	~$1,369
Class III — New Registration	$30,798	~$1,742
Class I / Low Risk — Renewal	$12,374	~$700
Class II — Renewal	$18,149	~$1,027
Class III — Renewal	$23,098	~$1,307

Government fees are paid per registration and are denominated in Mexican pesos. The USD equivalents above are approximate and will fluctuate with the exchange rate.

Total Cost Estimates by Classification

Government fees represent only a fraction of the total cost of registration. The following table provides realistic total cost estimates including MRH fees, regulatory consulting, document preparation, translation, and government fees:

Classification	Upfront Costs (Total)	Typical Timeline	Ongoing Annual Costs
Low Risk Notification	$1,000 - $2,000	~30 business days	~$5,000/year
Class I (Equivalency Route)	$3,000 - $4,000	~30 business days	~$5,000/year
Class II/III (Equivalency Route)	$5,000 - $7,000	~30 business days	~$5,000/year
Class II/III (Standard Route)	$10,000 - $20,000+	3-12+ months	~$5,000/year

The ongoing costs cover MRH retainer fees, technovigilance management, registration maintenance, and renewal preparation.

Cost Optimization Strategies

• Use the Equivalency Route whenever possible — The documentation preparation costs are significantly lower than preparing a full technical dossier for the Standard Route.
• Batch registrations — If you have multiple devices in the same family, explore whether COFEPRIS will accept a grouped submission to reduce per-device costs.
• Leverage MDSAP — If you already hold an MDSAP certificate, it satisfies the GMP evidence requirement for both Standard and Equivalency routes, eliminating the need for a separate GMP inspection.
• Plan renewals strategically — With the 2026 reform allowing subsequent renewals of up to 10 years, longer renewal cycles reduce the frequency of renewal costs.

2026 Regulatory Changes and Updates

The 2025-2026 period has seen significant regulatory reform in Mexico's medical device framework. Manufacturers planning market entry should be aware of the following changes:

General Health Law Reform (January 2026)

The most impactful change is the reform of Article 376 of the General Health Law, which now allows subsequent registration renewals to be valid for up to 10 years. Previously, all registrations (initial and renewal) were valid for 5 years. Under the reform:

• Initial registration: Still 5 years
• First renewal and beyond: Up to 10 years per renewal cycle

This change reduces the administrative burden and cost of maintaining registrations long-term and brings Mexico's renewal framework more in line with other major markets.

Abbreviated Pathway Operationalization (September 2025 - Early 2026)

The Equivalency Route was formally launched in September 2025 and became fully operational in early 2026. Key milestones:

• September 2025: Abbreviated pathway framework published and operational
• Early 2026: First fast-track registrations granted under the 30-business-day target
• Recognition of IMDRF/MDSAP approvals explicitly incorporated into the equivalency framework

Import Tariff Changes (January 2026)

New import tariffs for medical device products from countries without a free trade agreement with Mexico took effect in January 2026. Products from USMCA member countries (US, Canada) are not affected, but manufacturers sourcing from non-FTA countries should factor in potential tariff increases when calculating landed costs.

Consolidated Registration Procedures (2025)

COFEPRIS consolidated previously separate registration procedures into two unified Homoclave codes:

Homoclave	Procedure	Scope
COFEPRIS-04-060	Medical Device Health Registry	All medical devices — domestic, imported, and contract-manufactured (Class II and III)
COFEPRIS-04-070	Low-Risk Medical Device Health Registry	Low-risk devices — domestic and imported (Class I)

This consolidation eliminates the previous fragmentation where domestic, imported, and contract-manufactured devices each required separate application procedures. Under the new structure, a single application type covers all manufacturing origins within each risk tier.

Process Simplification Measures (March 2025)

In March 2025, COFEPRIS implemented a set of administrative simplification measures designed to reduce bureaucratic steps and improve processing efficiency. These measures include:

• Reduced documentation requirements for certain low-risk devices
• Streamlined administrative procedures for registration amendments
• Simplified renewal processes for devices with no changes since initial registration

Updated Standards

• NOM-241-SSA1-2025: The new GMP standard for medical devices, replacing the prior version. Manufacturers must comply with the updated requirements.
• Mexican Pharmacopoeia updates: Including new guidance for Software as a Medical Device (SaMD), reflecting the growing importance of digital health products in the Mexican market.

Summary of 2025-2026 Regulatory Timeline

Date	Change
March 2025	Simplification measures — reduced bureaucratic steps
September 2025	Abbreviated pathway (equivalency route) launched
January 2026	General Health Law reform — renewals up to 10 years
January 2026	New import tariffs for non-FTA countries
2025-2026	NOM-241-SSA1-2025 new GMP standard in effect
2025-2026	Mexican Pharmacopoeia updates including SaMD guidance
2025-2026	Equivalency route recognizes IMDRF/MDSAP approvals

Post-Market Obligations and Technovigilance

Obtaining a sanitary registration from COFEPRIS is not the end of your regulatory obligations in Mexico. The post-market framework requires ongoing compliance and active surveillance.

Technovigilance System

Mexico's technovigilance system requires the reporting of adverse events and field safety corrective actions related to medical devices. Key requirements include:

• Adverse event reporting — Serious adverse events must be reported to COFEPRIS within defined timeframes. The MRH typically manages this reporting process on behalf of the foreign manufacturer.
• Periodic safety reports — Manufacturers may be required to submit periodic safety update reports summarizing the global safety profile of their devices.
• Field safety corrective actions — Recalls, safety alerts, and other corrective actions taken in any market must be communicated to COFEPRIS if they affect devices distributed in Mexico.
• Trend reporting — Significant trends in adverse events that do not meet the threshold for individual reporting may need to be reported.

Registration Renewals

Sanitary registrations must be renewed before expiration. Under the 2026 reform:

• Initial registrations are valid for 5 years
• Subsequent renewals can be valid for up to 10 years

Renewal applications should be submitted well in advance of the expiration date to avoid any gap in market authorization. The renewal process requires demonstration that the device continues to meet regulatory requirements and that the manufacturer remains in compliance with GMP standards.

Import Permits

Class III devices require specific import permits in addition to the sanitary registration. The MRH coordinates the import permit process, which involves demonstrating that the imported device is covered by a valid registration and meets all applicable requirements.

COFEPRIS Inspections and Market Surveillance

COFEPRIS conducts inspections and market surveillance activities including:

• GMP inspections of manufacturing facilities (or relies on MDSAP audit reports)
• Distribution channel inspections to verify that devices are properly stored, labeled, and distributed
• Post-market surveillance testing to verify device performance and safety
• Advertising and promotion review to ensure compliance with Mexican regulations

Manufacturers should be prepared for the possibility of COFEPRIS inspections or requests for information at any time during the registration lifecycle.

Common Mistakes That Delay Approvals

Based on the experience of manufacturers who have navigated the COFEPRIS registration process, the following are the most common mistakes that cause delays:

1. Incorrect Classification

Submitting under the wrong risk class results in the application being returned or reclassified, adding weeks or months to the timeline. Always verify classification before preparing the dossier.

2. Incomplete or Inaccurate Spanish Labeling

NOM-137-SSA1-2008 requirements are specific and non-negotiable. Common issues include missing required elements on the label, inaccurate translations, and discrepancies between the Spanish labeling and the source documentation.

3. Inadequate Equivalence Justification (Equivalency Route)

For the fast-track pathway, the equivalence justification must clearly demonstrate that the device for the Mexican market is the same as the device approved by the reference authority. Differences in materials, manufacturing sites, or intended use that are not explained will trigger additional questions and delays.

4. Choosing the Wrong MRH

An inexperienced or unresponsive MRH can slow down every step of the process. The MRH is your interface with COFEPRIS — their competence directly impacts your timelines.

5. Missing or Expired Documents

Free Sale Certificates, ISO 13485 certificates, and other supporting documents have expiration dates. Submitting expired documents is one of the most common reasons for application rejection.

6. Insufficient Lead Time for Document Legalization

Foreign documents that require apostille or consular legalization can take weeks to process. Build this lead time into your project plan.

7. Underestimating Actual Timelines (Standard Route)

While COFEPRIS has statutory review periods of 20-180 days depending on class, actual processing times for the Standard Route have historically been 12 months or more. Do not plan your commercial launch based on statutory timelines alone.

8. Not Leveraging the Equivalency Route

Many manufacturers who are eligible for the fast-track equivalency pathway still submit through the Standard Route, either because they are unaware of the option or because they believe the Standard Route is more reliable. For devices with FDA, Health Canada, or Japan PMDA approval, the Equivalency Route is almost always the faster and more cost-effective choice.

Practical Tips for Market Entry

Start with the Equivalency Route if You Can

If your device has FDA clearance or approval, a Health Canada Medical Device License, or Japan PMDA authorization, use the Equivalency Route. It is faster, less expensive, and requires less documentation than the Standard Route. The 30-business-day target review period makes Mexico one of the faster regulatory pathways in Latin America for devices with established reference-market approvals.

Invest in Your MRH Relationship

Your MRH is the single most important partner in your Mexican market entry. Choose carefully, negotiate clear service level agreements, and maintain regular communication. A strong MRH relationship pays dividends throughout the product lifecycle.

Plan Your Spanish Documentation Early

Translation and localization of labeling and IFU into Spanish is not an afterthought. Begin the translation process early, use translators with medical device regulatory expertise, and build in time for review and correction. NOM-137 compliance is a frequent source of delays.

Coordinate with Your USMCA Strategy

If you are already selling in the US or Canada, Mexico should be a natural extension of your North American regulatory strategy. Leverage your existing FDA or Health Canada submissions, MDSAP certification, and quality system documentation to streamline the COFEPRIS process.

Budget Realistically

Government fees are relatively modest, but total registration costs — including MRH fees, consulting, translation, document preparation, and legalization — can range from a few thousand dollars for a simple low-risk notification to $20,000 or more for a complex Class III device through the Standard Route. Budget accordingly and factor in ongoing annual costs for registration maintenance.

Monitor Regulatory Changes

The Mexican regulatory landscape is evolving rapidly. The 2025-2026 reforms represent the most significant changes in years, and further updates are expected. Stay informed through your MRH, industry associations, and COFEPRIS communications.

Consider Brazil and Canada Simultaneously

If you are expanding into Latin America, consider pursuing Brazil's ANVISA registration and Canada's Health Canada Medical Device License in parallel with COFEPRIS registration. All three markets can leverage MDSAP certification and, in many cases, the same core technical documentation. See our guides on Brazil ANVISA registration and Canada Health Canada device licensing for more information.

Related Resources

• Brazil ANVISA Medical Device Registration: The Complete Guide — Regulatory requirements for Latin America's largest medical device market
• Canada Health Canada Medical Device License Guide — Registration pathways for the Canadian market
• ISO 13485 Certification Guide — Quality management system requirements recognized by COFEPRIS
• MDSAP Audit Guide — How the Medical Device Single Audit Program streamlines multi-market GMP compliance, including Mexico